Targeted, On-Demand Charge Conversional Nanotherapeutics for Advanced Prostate Cancer
Annual rept. 29 Aug 2013 28 Aug 2014
UTAH UNIV SALT LAKE CITY
Pagination or Media Count:
In this project, we have proposed to design and test an innovative nanotherapeutic system to attack prostate cancer occurred in skeletal tissue. The proposed targeted, bio-responsive nanotherapeutics are based on peptide-functionalized diblock copolymers of polyethylene glycol and polytrimethenecarbonate PEG-PTMC as the drug carrier, by using docetaxel as the therapeutic agent. During the first reporting period, copolymers with predetermined terminal functionality, molecular weights and chemical compositions have been synthesized, and the physicochemical properties of nanotherapeutics including drug loading capacity and drug release profile have been investigated. The peptide functionalized nanotherapeutics possess high HA binding affinity, indicating their good bone-targeting capacity. For the future study, in vivo bone uptake and retention of the nanotherpeutics in mice will be performed. The nanotherapeutics also will be investigated in cultured prostate cells to determine biological properties in terms of cathepsin K-triggered cellular uptake and anti-tumor efficacy. Finally, the proposed nanotherapeutics will be tested in mice with prostate cancer induced bone metastases.
- Medicine and Medical Research